Paradigm Health Acquires Flatiron Health’s Clinical Research Unit

Paradigm Health has successfully raised $78 million and completed the acquisition of Flatiron Health’s Clinical Research Business. This strategic move significantly alters the landscape of oncology trials in the United States, aiming to enhance patient access and streamline research processes nationwide.

By merging with Flatiron Health, Paradigm Health combines its extensive technology-enabled oncology research network with an advanced, AI-powered trial infrastructure. This integration is designed to create a cohesive ecosystem that expands trial capacity, reduces operational complexities, and provides more representative evidence for clinical research.

Expanding Reach and Impact

The acquisition enables Paradigm Health to extend its network to over 25 academic medical centers and health systems, alongside nearly 100 community oncology practices and more than 2.4 million patients across the country. This broadened presence allows clinical trials to occur where patients already receive care, rather than relying solely on a limited number of high-volume research centers. This shift is particularly vital for rural and underserved populations, who often face challenges in accessing clinical research opportunities.

Flatiron Health’s established research tools, which revolve around its OncoEMR network and relationships within community practices, will be seamlessly integrated into Paradigm’s end-to-end platform. This alignment allows research sponsors and clinical sites to engage in a unified, AI-enabled workflow that enhances documentation processes, expedites feasibility assessments, and diminishes the operational burden typically incurred by clinical sites.

A Pathway to Modernized Clinical Research

Both Paradigm Health and Flatiron Health emphasize their commitment to ensuring a smooth transition for health systems and community clinics. The partnership is designed to maintain existing research relationships while injecting advanced digital capabilities into their operations. This collaboration not only bolsters Paradigm’s capacity to support biopharmaceutical sponsors comprehensively but also facilitates the execution of pragmatic Phase IV studies embedded within real-world care settings. This approach accelerates the generation of relevant post-market evidence.

By leveraging their complementary strengths, Paradigm Health and Flatiron Health are poised to transform the U.S. clinical research ecosystem, making it more inclusive, efficient, and aligned with national priorities for modernizing trial delivery. Their shared objective is clear: to establish a research infrastructure that accurately reflects real-world populations, reduces barriers for healthcare providers, and expands trial access in community settings. Ultimately, this initiative aims to expedite the delivery of new therapies to patients.

The terms of the transaction have not been disclosed, but the implications for the oncology research landscape are expected to be significant.